Top Markets
#1 Seeker Seeker +133.86%
#2 AI XOVIA AI XOVIA +102.03%
#3 Helium Helium +70.79%
#4 MowCat MowCat +68.76%
#5 Pons Pons +40.10%
#6 UnifAI Network UnifAI Network +34.88%
#7 Zora Zora +31.89%
#8 Zylo Ecosystem Zylo Ecosystem +20.92%
#9 Bounce Bounce +20.57%
#10 TENDIES TENDIES +19.28%
Coin of the day
Seeker Seeker
Innstillinger
Språk
NORSK
Valuta
USD
Tema
AgomAb Therapeutics N.V. American Depositary Shares AgomAb Therapeutics N.V. American Depositary Shares

AgomAb Therapeutics N.V. American Depositary Shares

AGMB
Rangering i aksjer #11835
AgomAb Therapeutics N.V. is a clinical-stage biopharmaceutical company... AgomAb Therapeutics N.V. is a clinical-stage biopharmaceutical company dedicated to developing novel, disease-modifying therapies. Its primary focus lies in immunology and inflammatory ailments, particularly chronic fibrotic conditions where significant unmet medical needs persist. Its innovative pipeline features several promising candidates, including Ontunisertib (AGMB-129), an orally administered, gastrointestinal-restricted small molecule inhibitor targeting ALK5 or TGFßR1, designed to treat Fibrostenosing Crohn's disease and presently undergoing Phase 2a clinical trials. Also in development is AGMB-447, an inhaled small molecule that similarly inhibits ALK5 or TGFßR1, intended for idiopathic pulmonary fibrosis and currently in Phase 1 clinical studies. Furthermore, the company is advancing AGMB-101, a monoclonal antibody designed to mimic HGF. This agent exerts its effects through the agonism or stimulation of the MET receptor, having demonstrated both antifibrotic and regenerative capabilities in preclinical models. Established in 2017, AgomAb Therapeutics maintains its headquarters in Antwerp, Belgium.
Aksjekurs
$13.26
Sist synkronisert: 2026-08-28
Markedsverdi
$653.15M
Endring (1 dag)
-4.17%
Endring (1 år)
-
Land
BE
Handel AgomAb Therapeutics N.V. American Depositary Shares (AGMB)

Kategori

Healthcare
P/E-forhold for AgomAb Therapeutics N.V. American Depositary Shares (AGMB)
P/E-forhold per 2026 TTM: 0
Ifølge AgomAb Therapeutics N.V. American Depositary Shares sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet en P/E på 0.
P/E-forholdshistorikk for AgomAb Therapeutics N.V. American Depositary Shares fra 2026 til 2026
P/E-forhold ved slutten av hvert år
År P/E-forhold Endre
Ikke nok data for de angitte datoene.
P/E-forhold for lignende selskaper eller konkurrenter
Selskap P/E-forhold Forskjell i P/E-forhold Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Hvordan lese en P/E-ratio?

Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.

Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.

Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.